kras

Skip to content The CRC Digest ◇ KRAS-mutant colorectal cancers show variable response to RAS inhibitors Preclinical research found that KRAS-mutant colorectal cancer models respond differently to RAS(ON) inhibitor RMC-7977 based on PI3K signaling and cyclin D1 expression patterns, with combined RAS and PI3K inhibition showing synergistic effects in some

Skip to content The CRC Digest Novel SOS1 Inhibitors Show Potent Activity Against KRAS-Driven CRC Highly potent and selective SOS1 inhibitors disrupted the SOS1-KRAS interaction, inhibited nucleotide exchange in wild-type and multiple KRAS variants, and showed submicromolar anti-proliferative activity in colorectal cancer cells. (J Med Chem) This content is informational